Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  04:58 2022-07-05 am EDT
10769.00 GBX   -0.36%
03:43aAstraZeneca Moves to Boost Blood Cancer Pipeline Via $1.3 Billion TeneoTwo Acquisition
MT
03:30aAstraZeneca to Buy TeneoTwo in Up to $1.27 Billion Deal
MT
02:24aAstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
11054(c) 10794(c) 10722(c) 10822(c) 10796 Last
1 504 553 2 377 056 1 981 487 665 137 128 442 Volume
+2.48% -2.35% -0.67% +0.93% -0.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 43 717 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 403 M - -
P/E ratio 2022 40,4x
Yield 2022 2,25%
Sales 2023 46 687 M - -
Net income 2023 8 020 M - -
Net Debt 2023 20 158 M - -
P/E ratio 2023 25,4x
Yield 2023 2,36%
Capitalization 203 B 203 B -
EV / Sales 2022 5,20x
EV / Sales 2023 4,78x
Nbr of Employees 83 100
Free-Float 96,4%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious... 
Read more
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ASTRAZENECA PLC
03:43aAstraZeneca Moves to Boost Blood Cancer Pipeline Via $1.3 Billion TeneoTwo Acquisition
MT
03:30aAstraZeneca to Buy TeneoTwo in Up to $1.27 Billion Deal
MT
02:24aAstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion
RE
02:23aAstraZeneca To Buy TeneoTwo in Up tp $1.27 Billion Deal
MT
12:31aAstraZeneca to Buy TeneoTwo for Up to $1.27 Billion
DJ
07/01SECTOR UPDATE : Health Care Stocks Rebound Late
MT
07/01SECTOR UPDATE : Health Care Stocks Struggling for Direction
MT
07/01AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
MT
07/01AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination..
BU
07/01AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® Combinations in Patients..
CI
07/01AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica
MT
07/01New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten ..
AQ
07/01Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN..
AQ
07/01Pharmaceutical companies still have the upper hand
07/01Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
DJ
More news
News in other languages on ASTRAZENECA PLC
03:57aASTRAZENECA : acquisition de TeneoTwo
03:43aAstraZeneca cherche à renforcer son portefeuille de produits pour le traitement du canc..
03:30aAstraZeneca va racheter TeneoTwo pour un montant maximum de 1,27 milliard de dollars.
03:07aLe retour du duty free ?
02:36aEN DIRECT DES MARCHES : Renault, Valeo, Elis, Valora, Sainsbury, Uniper, SAS, AstraZeneca,..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Analysis
Pharmaceutical companies still have the upper hand
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 130,92 $
Average target price 142,37 $
Spread / Average Target 8,74%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC24.71%202 861
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782